检查沙布塔摩尔使用对运动引起的支气管收缩患者臭氧空气污染的影响
Bennett T Stothers1, Andy Hung1, Patric E O Gonçalves1
1University of British Columbia, Vancouver, Canada.
Physiological reports
|October 29, 2024
概括
在暴露于臭氧时,萨尔布塔摩尔可以安全地改善运动诱导支气管收缩 (EIB) 患者的肺功能. 这项研究没有发现呼吸道炎症增加,这表明当臭氧水平高时,继续使用是安全的.
科学领域:
- 环境健康 环境健康
- 肺部病理学 肺部病理学
- 药理学 药理学是指药理学的学科.
背景情况:
- 动物模型表明,暴露在臭氧中可能会加剧使用萨尔布塔摩尔的肺部损伤.
- 运动引起的支气管收缩 (EIB) 是一种常见的呼吸道疾病.
- 在空气污染事件期间使用支气管扩展剂的安全性存在担忧.
研究的目的:
- 研究salbutamol在与EIB在臭氧污染空气中炼的个体中的安全性和有效性.
- 为了确定沙布塔摩尔是否会加剧臭氧诱导的肺炎.
主要方法:
- 这是一项双盲,随机,安慰剂控制的交叉研究,涉及18名EIB受试者.
- 试验对象在四种条件下进行了30分钟的运动:臭氧/萨尔布他,室内空气/萨尔布他,臭氧/安慰剂,室内空气/安慰剂.
- 运动前和运动后的测量螺旋计 (FEV1) 和呼出的氧化 (FeNO) 分数.
主要成果:
- 与安慰剂相比,萨尔布塔摩尔显著改善了FEV1 (p < 0.001).
- 在臭氧和室内空气暴露之间没有观察到肺功能或FeNO的显著差异.
- 在这两种情况下,沙尔布塔摩尔都没有增加异性气道炎症 (FeNO).
结论:
- 在臭氧污染的环境中炼的EIB患者,萨尔布塔摩尔是安全有效的.
- 目前的证据表明,即使臭氧水平升高,也可以按照规定使用沙布塔摩尔.
- 这项研究提供了人类数据,以减轻人们对 EIB 患者在臭氧暴露期间使用沙布他的担忧.
相关概念视频
Antiasthma Drugs: β2-Adrenoceptor Agonists
234
Bronchodilators are critical in managing asthma, a chronic respiratory condition characterized by airway constriction due to inflammation and hyper-reactivity. Specifically, bronchodilators ease this constriction by relaxing the bronchial muscles, facilitating easier breathing.
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce...
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce...
234
COPD: Management Using Bronchodilators and Corticosteroids
182
Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...
182
Asthma: Pathogenesis and Management
361
Asthma is a chronic pulmonary condition involving inflammation of the airways, hyper-reactivity, and reversible obstruction of the airways. This condition can significantly impact a person's quality of life, making breathing difficult and leading to distressing symptoms.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
361
Drugs Used in Lower Respiratory Disorders: Overview
353
Lower respiratory tract disorders present challenges that often require skilled and nuanced approaches for effective management. Common ailments, such as asthma and chronic obstructive pulmonary disease (COPD), have prompted the development of intricate treatment strategies involving bronchodilators and anti-inflammatory drugs, each tailored to ease breathing and revitalize the lungs.
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
353
Antiasthma Drugs: Muscarinic Receptor Antagonists
249
Muscarinic receptor antagonists, also known as antimuscarinic agents, are a class of bronchodilators used to treat asthma, although they are more commonly used to treat COPD. They work by inhibiting the action of acetylcholine (ACh), a neurotransmitter, on muscarinic receptors found in the airways.
Antimuscarinic agents compete with ACh for the same binding site on the muscarinic receptors. By binding to these receptors, they inhibit the downstream effects of ACh and block the parasympathetic...
Antimuscarinic agents compete with ACh for the same binding site on the muscarinic receptors. By binding to these receptors, they inhibit the downstream effects of ACh and block the parasympathetic...
249
Chronic Obstructive Pulmonary Disease-II: Pathophysiology
2.7K
Chronic Obstructive Pulmonary Disease (COPD) pathophysiology is intricate and multifaceted, involving a complex interplay of physiological processes. Understanding these mechanisms is crucial for effectively managing and treating COPD. Here is an in-depth look at the critical elements in the pathophysiology of COPD:
Chronic Inflammation
Chronic Inflammation
2.7K


